SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sharps Technology, Inc. STSS NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sharps Technology, Inc. (STSS) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $1.74. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: STSS trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Financials: revenue is $204,120, +0%/yr average growth. Net income is $283M (loss), growing at -1431.8%/yr. Net profit margin is -138400% (negative). Gross margin is -202.5% (+0 pp trend).

Balance sheet: total debt is $3M against $264M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 2.39 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $269M.

Analyst outlook: 1 / 1 analysts rate STSS as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 67/100 (Partial), Moat 11/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

STSS SharesGrow Score Overview

38/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 11/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — STSS

No analyst coverage available for this stock.

STSS: +0%/yr revenue is, -1431.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

STSS: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet STSS: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 2.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

STSS: Gross margin is -202.5% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 11/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate STSS as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

STSS: Net profit margin is -138400%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.415-18.23

Volume307.11K

Avg Volume (30D)457.57K

Market Cap$44.4M

Beta (1Y)2.20

Share Statistics

EPS (TTM)-11.16

Shares Outstanding$25.31M

IPO Date2022-04-14

Employees55

CEOPaul Kruger Danner

Financial Highlights & Ratios

Revenue (TTM)$204.12K

Gross Profit$-413.33K

EBITDA$-269.74M

Net Income$-282.5M

Operating Income$-269.74M

Total Cash$10.38M

Total Debt$3.08M

Net Debt$-7.3M

Total Assets$269.08M

Price / Earnings (P/E)-0.2

Price / Sales (P/S)217.5

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS82003F3091

Price Chart

STSS

Sharps Technology, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Instruments & Supplies

1.42 52WK RANGE 18.23

People Also View

Utah Medical Products, Inc.

InfuSystem Holdings, Inc.

KORU Medical Systems, Inc.

Microbot Medical Inc.

Precision Optics Corporation, Inc.

Milestone Scientific Inc.

Jin Medical International Ltd.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message